Venture capital firm Boson Ventures is highlighting the missed opportunities for Australian biotechnology startups in tapping into China’s rapidly growing pharmaceutical market. With China’s transition from being dependent on Western drugs to becoming a key player in global pharmaceutical innovation, Australian companies are encouraged to explore collaborations in the thriving Chinese biotech ecosystem.
Betty Zhang, an investment manager at Boson Ventures, notes the significant shift in China’s focus on research and development, leading to the country’s increased R&D spending and dominance in total clinical trials. This evolution presents a strategic opportunity for Australian deep tech companies to leverage China’s expanding biotech landscape and establish fruitful partnerships for mutual growth and innovation.
Read more on capitalbrief.com